1Barber, MD, Ross, JA & Fearon, KC (1999) Cancer cachexia. Surg Oncol 8, 133–141.
2Larkin, M (1998) Thwarting the dwindling progression of cachexia. Lancet 351, 1336.
3Tisdale, MJ (1997) Biology of cachexia. J Natl Cancer Inst 89, 1763–1773.
4Azhar, G & Wei, JY (2006) Nutrition and cardiac cachexia. Curr Opin Clin Nutr Metab Care 9, 18–23.
5Bosaeus, I, Daneryd, P & Lundholm, K (2002) Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 132, 3465S–3466S.
6Dewys, WD, Begg, C, Lavin, PT, et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69, 491–497.
7Kotler, DP, Tierney, AR, Culpepper-Morgan, JA, et al. (1990) Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr 14, 454–458.
8Anker, SD & Sharma, R (2002) The syndrome of cardiac cachexia. Int J Cardiol 85, 51–66.
9Delano, MJ & Moldawer, LL (2006) The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 21, 68–81.
10Klaude, M, Fredriksson, K, Tjader, I, et al. (2007) Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin Sci (Colch) 112, 499–506.
11Melstrom, LG, Melstrom, KA Jr, Ding, XZ, et al. (2007) Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 22, 805–814.
12Büntzel, J & Küttner, K (1995) Value of megestrol acetate in treatment of cachexia in head–neck tumors (article in German). Laryngorhinootologie 74, 504–507.
13Lees, J (1999) Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl) 8, 133–136.
14Palesty, JA & Dudrick, SJ (2003) What we have learned about cachexia in gastrointestinal cancer. Dig Dis 21, 198–213.
15Jagoe, RT & Goldberg, AL (2001) What do we really know about the ubiquitin–proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4, 183–190.
16Gomes, MD, Lecker, SH, Jagoe, RT, et al. (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 98, 14440–14445.
17Bodine, SC, Latres, E, Baumhueter, S, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704–1708.
18Wray, CJ, Mammen, JMV, Hershko, DD, et al. (2003) Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 35, 698–705.
19Lecker, SH, Jagoe, RT, Gilbert, A, et al. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18, 39–51.
20Dehoux, MJM, van Beneden, RP, Fernandez-Celemin, L, et al. (2003) Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett 544, 214–217.
21Jones, SW, Hill, RJ, Krasney, PA, et al. (2004) Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. FASEB J 18, 1025–1027.
22Di Giovanni, S, Molon, A, Broccolini, A, et al. (2004) Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 55, 195–206.
23Siddiqui, R, Pandya, D, Harvey, K, et al. (2006) Nutrition modulation of cachexia/proteolysis. Nutr Clin Pract 21, 155–161.
24Haslett, PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25, 53–57.
25Ng, EH & Lowry, SF (1991) Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 5, 161–184.
26Inui, A (2002) Cancer anorexia–cachexia syndrome: current issues in research and management. CA Cancer J Clin 52, 72–91.
27Ammon, HP & Wahl, MA (1991) Pharmacology of Curcuma longa. Planta Med 57, 1–7.
28Miquel, J, Bernd, A, Sempere, JM, et al. (2002) The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 34, 37–46.
29Joe, B, Vijaykumar, M & Lokesh, BR (2004) Biological properties of curcumin – cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 44, 97–111.
30Goel, A, Kunnumakkara, AB & Aggarwal, BB (2008) Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol 75, 787–809.
31Aggarwal, BB, Shishodia, S, Takada, Y, et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490–7498.
32Shishodia, S, Chaturvedi, MM & Aggarwal, BB (2007) Role of curcumin in cancer therapy. Curr Probl Cancer 31, 243–305.
33Jana, NR, Dikshit, P, Goswami, A, et al. (2004) Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 279, 11680–11685.
34Wyke, SM, Russell, ST & Tisdale, MJ (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κB activation. Br J Cancer 91, 1742–1750.
35Jin, B & Li, Y-P (2007) Curcumin prevents lipopolysaccharide-induced atrogin-1/MAFbx upregulation and muscle mass loss. J Cell Biochem 100, 960–969.
36Thaloor, D, Miller, KJ, Gephart, J, et al. (1999) Systemic administration of the NF-κB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 277, C320–C329.
37Busquets, S, Carbo, N, Almendro, V, et al. (2001) Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 167, 33–38.
38Pan, MH, Huang, TM & Lin, JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27, 486–494.
39Sharma, RA, Euden, SA, Platton, SL, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 6847–6854.
40Lao, CD, Ruffin, MTIV, Normolle, D, et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6, 10.
41Garcea, G, Berry, DP, Jones, DJ, et al. (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14, 120–125.
42Marczylo, TH, Verschoyle, RD, Cooke, DN, et al. (2007) Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60, 171–177.
43Whitehouse, AS & Tisdale, MJ (2003) Increased expression of the ubiquitin–proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB. Br J Cancer 89, 1116–1122.
44Beck, SA & Tisdale, MJ (1987) Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 47, 5919–5923.
45Smith, HJ, Mukerji, P & Tisdale, MJ (2005) Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res 65, 277–283.
46Cai, D, Frantz, JD, Tawa, NE Jr, et al. (2004) IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 119, 285–298.
47Mitch, WE & Goldberg, AL (1996) Mechanisms of muscle wasting. The role of the ubiquitin–proteasome pathway. N Engl J Med 335, 1897–1905.
48Breen, HB & Espat, NJ (2004) The ubiquitin–proteasome proteolysis pathway: potential target for disease intervention. JPEN J Parenter Enteral Nutr 28, 272–277.
49Llovera, M, Garcia-Martinez, C, Agell, N, et al. (1995) Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 61, 138–141.
50Hasselgren, PO (1999) Role of the ubiquitin–proteasome pathway in sepsis-induced muscle catabolism. Mol Biol Rep 26, 71–76.
51Llovera, M, Carbo, N, Lopez-Soriano, J, et al. (1998) Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 133, 83–87.
52Llovera, M, Garcia-Martinez, C, Agell, N, et al. (1997) TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 230, 238–241.
53Garcia-Martinez, C, Llovera, M, Agell, N, et al. (1994) Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-α. Biochem Biophys Res Commun 201, 682–686.
54Lecker, SH, Solomon, V, Mitch, WE, et al. (1999) Muscle protein breakdown and the critical role of the ubiquitin–proteasome pathway in normal and disease states. J Nutr 129, 227S–237S.
55Hobler, SC, Tiao, G, Fischer, JE, et al. (1998) Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. Am J Physiol 274, R30–R37.
56Stitt, TN, Drujan, D, Clarke, BA, et al. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14, 395–403.
57Sandri, M, Sandri, C, Gilbert, A, et al. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399–412.
58Latres, E, Amini, AR, Amini, AA, et al. (2005) Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 280, 2737–2744.
59Li, Y-P, Chen, Y, John, J, et al. (2005) TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 19, 362–370.
60Li, Y-P, Lecker, SH, Chen, Y, et al. (2003) TNF-α increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17, 1048–1057.
61Li, YP & Reid, MB (2000) NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 279, R1165–R1170.
62Poylin, V, Fareed, MU, O'Neal, P, et al. (2008) The NF-κB inhibitor curcumin blocks sepsis-induced muscle proteolysis. Mediators Inflamm 2008, 317851.
63Jobin, C, Bradham, CA, Russo, MP, et al. (1999) Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 163, 3474–3483.
64Durham, WJ, Arbogast, S, Gerken, E, et al. (2006) Progressive nuclear factor-κB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 34, 298–303.
65Carter, Y, Liu, G, Yang, J, et al. (2003) Sublethal hemorrhage induces tolerance in animals exposed to cecal ligation and puncture by altering p38, p44/42, and SAPK/JNK MAP kinase activation. Surg Infect (Larchmt) 4, 17–27.